The 42nd JP Morgan Healthcare Conference is set to take place from Jan. 8 to 11 in San Francisco, California, in the U.S. This annual event, held every January, is renowned as the world’s largest healthcare investment venue where major global pharmaceutical companies, emerging biotech firms, and pro
Dong-A ST announced on Jan. 4 that it has signed a license-in agreement with SK Biopharmaceuticals to license out its new epilepsy drug Cenobamate in 30 countries including Korea, Southeast and Southwest Asia, Russia, Australia, New Zealand, and Turkiye.Under the agreement, Dong-A ST will receive dr
SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system (CNS) disorders and oncology, will present data on cenobamate at the American Epilepsy Society (AES) Annual Meeting, to be h
SK biopharmaceuticals has received Canadian market approval for its newly developed cenobamate epilepsy drug sold under the local product name Xcopri.On June 14, SK biopharmaceuticals announced that Health Canada had issued a Notice of Compliance for cenobamate, approving its application for market
SK Inc., together with its life science affiliates including SK biopharmaceuticals and SK pharmteco, will hold a networking event to expand their global partnerships in the U.S., the world’s largest bio and pharmaceutical market. SK Inc. is the strategic investment holding company of Korea’s SK Grou
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. SK Biopharm posted consolidated 3Q22 sales of W88.8bn and an operating loss of W9.2bn, beating consensus. The firm’s operating loss narrowed on the booking of W19.6bn in licensing out fees for Cenoba
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. We expect SK Biopharm to deliver consolidated 3Q22 sales of W79.2bn and an operating loss of W18.7bn, coming in slightly below consensus. The firm’s operating loss should narrow, as upfront fees are
SK Biopharmaceuticals announced on Dec. 23 that it has licensed out Cenobamate technology to Endo International, a specialty pharmaceutical company based in Dublin, Ireland.Cenobamate is a medication used for the treatment of partial-onset seizures, a kind of epilepsy. It is sold under the brand nam
SK Biopharmaceuticals was recently sued for damages by a partner who hold the European sales rights to its own new drug, cenobamate, which is sold under the brand names Xcopri (U.S.) and Ontozry (EU). It is a medication used for the treatment of partial-onset seizures, a kind of epilepsy, in adults.
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. In a move to start operations in China, SK Biopharm established Ignis by obtaining issued stock for non-cash assets (Chinese distribution rights for six drugs/pipelines, including Xcopri). Further in
SK Biopharmaceuticals has established Ignis Therapeutics, a central nervous system (CNS) pharmaceutical company, with 6 Dimension Capital (6D), a global investment company based in Shanghai.SK Biopharm has acquired a 44.9 percent stake in Ignis Therapeutics by transferring the sales rights in China
The U.S. Food and Drug Administration is expected to conduct due diligence on Hanmi Pharmaceutical's plant in Pyeongtaek sometime in May. The FDA will inspect the production facilities for Hanmi’s neutrophilia drug Rolontis. Originally scheduled for October 2020, the due diligence was postponed
SK Group is stepping up its efforts to tap into the European biopharmaceutical market. SK Biopharmaceuticals has been given the green light to sell its new drug Cenobamate in Europe. The group has also completed the acquisition of French contract manufacturing organization (CMO) company Yposkesi.SK
SK Biopharm has licensed out its new drug Cenobamate, which has been approved by the U.S. Food and Drug Administration (FDA), to a Japanese company.The company announced on Oct. 13 that it has signed a deal with Ono Pharmaceutical of Japan to hand over the right to develop and commercialize Cenobama
SK Biopharm will begin clinical trials of Cenobamate (U.S. product name: Xcopri), a new epilepsy treatment, in Asia.SK Biopharm announced on Sept. 10 that the Korean Ministry of Food and Drug Safety approved its investigational new drug application (IND) on Sept. 9. The company is waiting for approv
The author is an analyst of KB Securities. He can be reached at newday@kbfg.com. -- Ed. Expectation of IPO for SK BiopharmSK Holdings stock skyrocketed 16.5% (as of 10:50 a.m.) on expectations of an IPO for SK Biopharm. Last month, the wholly owned subsidiary submitted a stock registration statement
SK BioPharm, a pharmaceutical unit of SK Group, announced on July 3 that its U.S. partner Jazz Pharmaceuticals will start sales of innovative new sleep disorder drug Solriamfetol (product name: Sunosi) in the U.S. market on July 8 following the FDA approval in March.This is the first time that an in
SK Group’s 20 year-long steady investment in new drug development has finally started to shine.SK Biopharm announced on Feb. 14 that it has forged a licensing agreement worth US$530 million with Swiss company Arvelle Therapeutics for the commercialization of cenobamate, a candidate antiepileptic dru
The SK Group is seeking to enter the U.S. drug market, the largest market in the world, with a self-developed new drug.The group announced on Nov. 26 that its subsidiary SK Biopharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Cenobamate, an